Regulatory peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analog of the tetrapeptide tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Reported consistently across pharmacopoeial descriptions |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| Solubility | Freely soluble in water | Aqueous buffers; poor in nonpolar solvents |
| Typical storage temperature | -20 degrees Celsius | Lyophilized powder; protect from moisture |
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
== History == Paliperidone palmitate was first approved by the United States Food and Drug Administration (FDA) on July 31, 2009, under the brand name Invega Sustenna, for the acute and maintenance treatment of schizophrenia in adults. Health Canada followed on June 30, 2010, issuing a Notice of Compliance for the same indication. Australia's Therapeutic Goods Administration registered the product on July 28, 2010. The European Medicines Agency (EMA) authorized the once‑monthly injection under the brand name Xeplion on March 4, 2011. In China, the drug was approved in January 2012 and launched later that year under the brand name Shansida (善思达); marketed by Xian-Janssen Pharmaceutical Limited (which is the Janssen (Johnson & Johnson) subsidiary in China), it was the first once-monthly long-acting injectable atypical antipsychotic available in the country. The approval was based on a multi-center clinical trial funded by Xian-Janssen Pharmaceutical Ltd. which demonstrated that Shansida monotherapy was non-inferior to a combination of oral risperidone and long-acting injectable risperidone microspheres (brand name Risperdal Consta) for acute schizophrenia. In Japan, the once‑monthly injection was approved in September 2013 under the brand name Xeplion (ゼプリオン, Zepurion) and was launched on November 19, 2013. Globally, the paliperidone palmitate long-acting injectable market was valued at approximately US$4.1 billion in 2024 and is projected to reach US$6.3 billion by 2031.
In another study, researchers evaluated synthetic platelet (SP) nanoparticles in mouse models of von Willebrand disease (vWD). In vitro, SPs enhanced thrombus formation under vWF-deficient conditions using human platelets. In vivo, SP treatment reduced blood loss by 35% in type 2B VWD mice and 68% in vWF knockout mice. These findings suggest that SPs may offer a promising therapeutic approach for managing bleeding in vWD. In vitro studies on SynthoPlate assessed its impact on thrombin and fibrin generation to evaluate its procoagulant potential. SynthoPlate did not induce spontaneous thrombin generation in human plasma but enhanced fibrin deposition under flow conditions by promoting platelet recruitment and aggregation on a collagen and vWF-coated surface. In vivo, a thrombocytopenic mouse model was used to assess SynthoPlate's hemostatic efficacy. Mice treated with SynthoPlate exhibited significantly reduced bleeding times following tail transection compared to controls, with effects observed within a two-hour circulation period. Immunostaining and immunoblotting confirmed enhanced fibrin formation at the injury site, indicating that SynthoPlate effectively supports clot formation in platelet-deficient conditions.
=== Prostate conditions === Spironolactone has been studied at a high dosage in the treatment of benign prostatic hyperplasia (BPH; enlarged prostate). It was found to be better than placebo in terms of symptom relief following three months of treatment. However, this was not maintained after six months of treatment, by which point the improvements had largely disappeared. Moreover, no difference was observed between spironolactone and placebo with regard to volume of residual urine or prostate size. Gynecomastia was observed in about 5% of people. On the basis of these results, it has been said that spironolactone has no place in the treatment of BPH. Spironolactone has been studied and used limitedly in the treatment of prostate cancer.
Sources: en.wikipedia.org
Tunable diode laser absorption spectroscopy (TDLAS, sometimes referred to as TDLS, TLS or TLAS) is a technique for measuring the concentration of certain species such as methane, water vapor and many more, in a gaseous mixture using tunable diode lasers and laser absorption spectrometry. The advantage of TDLAS over other techniques for concentration measurement is its ability to achieve very low detection limits (of the order of ppb). Apart from concentration, it is also possible to determine the temperature, pressure, velocity and mass flux of the gas under observation. TDLAS is by far the most common laser based absorption technique for quantitative assessments of species in gas phase.
== Hybrid closed-loop systems == Hybrid closed-loop (HCL) systems, also known as automated insulin delivery (AID) systems, are medical technologies designed to assist individuals with diabetes in regulating blood glucose levels. These systems integrate a continuous glucose monitor (CGM), an insulin pump, and a control algorithm to automatically adjust basal insulin delivery and, in some systems, administer correction boluses. The term "hybrid" refers to the fact that while the system automates many aspects of insulin dosing, users are still required to manually input carbohydrate intake and manually administer bolus doses for meals. HCL systems aim to maintain glucose levels within a target range and reduce the frequency and severity of hypoglycemia and hyperglycemia. Research and development of HCL systems began in the early 2000s, with efforts such as the Advanced Insulin Infusion Using a Control Loop (ADICOL) project. A 2008 clinical trial by Weinzimer et al. demonstrated that hybrid closed-loop therapy significantly improved overnight glucose control compared to conventional insulin delivery. The first HCL system to receive regulatory approval was the MiniMed 670G (Medtronic) in 2016. Since then, other systems—including the MiniMed 770G and 780G, Tandem t:slim X2 with Control-IQ, and CamAPS FX—have also been introduced, employing various algorithmic strategies such as model predictive control (MPC), proportional-integral-derivative (PID) control, and fuzzy logic.
=== Copper-64 DOTA-TATE === Copper (64Cu) oxodotreotide or copper Cu 64 dotatate, sold under the brand name Detectnet, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adults. It was FDA approved in September 2020. These are the same indications for as the gallium DOTA-TATE scans, but Cu-64 has advantages over Ga-68 in having a 12-hour half life rather than the much shorter one-hour half life of Ga-68, making it easier to transport from central production locations.
=== Australia === On 1 July 2024, Australia implemented a complete ban on the manufacture and use of engineered stone benchtops, panels, or slabs, and these products became prohibited imports on 1 January 2025. In doing so, it was the first country in the world to totally ban engineered stone countertops.
Sources: en.wikipedia.org
== Genetics and diseases == Hemoglobin D is synthesised due to mutation in HBB, the gene that produces β-subunits of hemoglobin and is present on human chromosome 11. A point mutation in the first base of the 121 codon that normally has GAA sequence for normal hemoglobin is changed to CAA. GAA codes for glutamic acid, while CAA for glutamine. This gene mutation makes HbD, which can further give rise to several genetic and disease conditions. The specific mutations can occur at different sites of the gene. According to the Globin Gene Server database, there are other types of HbD such as HbD-Agri (HBB:c.29C→A;364G→C), HbD-Bushman (HBB:c.49G→C), HbD-Ouled Rabah (HBB:c.60C→A or 60C→G), HbD-Iran (HBB:c.67G→C), HbD-Granada (HBB:c.68A→T), HbD-Ibadan (HBB:c.263C→A) and HbD-Neath (HBB:c.365A→C). Depending on the nature of inheritance of HbD mutation there are four conditions, some of which can be deadly diseases:
=== As a drug target === Because the specific activity of STAT5a has not been extensively investigated, most potential therapeutic treatments aim to target STAT5a/b. So far, the only reported potential therapeutic benefit specific to STAT5a has been in colorectal cancer. Inhibition of STAT5a alone would not effect colorectal cancer cells, but when combined with chemotherapies such as cisplatin, it could increase the chemosensitivity of the cancer cells to the drugs. Therapy schemes currently focus on STAT5a/b, targeting and inhibiting different mediators of the JAK2-STAT5 pathway.
1993/1789) Criminal Justice Act 1988 (Designated Countries and Territories) (Amendment) Order 1993 (S.I. 1993/1790) Criminal Justice (International Co-operation) Act 1990 (Enforcement of Overseas Forfeiture Orders) (Amendment) Order 1993 (S.I. 1993/1791) Drug Trafficking Offences Act 1986 (Designated Countries and Territories) (Amendment) Order 1993 (S.I. 1993/1792) Haiti (United Nations Sanctions) (Channel Islands) Order 1993 (S.I. 1993/1793) Haiti (United Nations Sanctions)(Isle of Man) Order 1993 (S.I. 1993/1794) Hong Kong (British Nationality) (Amendment) Order 1993 (S.I. 1993/1795) Immigration (Guernsey) Order 1993 (S.I. 1993/1796) Immigration (Jersey) Order 1993 (S.I. 1993/1797) Iraq (United Nations) (Sequestration of Assets) (Guernsey) Order 1993 (S.I. 1993/1798) Iraq (United Nations) (Sequestration of Assets) (Jersey) Order 1993 (S.I. 1993/1799)
The unidirectionality of the system is a result from both the asymmetric skew of the helicene moiety as well as the strain of the cyclic urethane which is formed in c. This strain can be only be lowered by the clockwise rotation of the triptycene rotor in d, as both counterclockwise rotation as well as the inverse process of d are energetically unfavorable. In this respect the preference for the rotation direction is determined by both the positions of the functional groups and the shape of the helicene and is thus built into the design of the molecule instead of dictated by external factors.
The outbreak of the French Revolution had been received with great alarm by the rulers of Europe's continental powers, further exacerbated by the execution of Louis XVI, and the overthrow of the French monarchy. In 1793, Austria, the Kingdom of Sardinia, the Kingdom of Naples, Prussia, the Kingdom of Spain, and the Kingdom of Great Britain formed the First Coalition to curtail the growing power of revolutionary France. Measures such as mass conscription, military reforms, and total war allowed France to defeat the coalition, despite the concurrent civil war in France. Napoleon, then a general of the French Revolutionary Army, forced the Austrians to sign the Treaty of Campo Formio, leaving only Great Britain opposed to the fledgling French Republic. A Second Coalition was formed in 1798 by Great Britain, Austria, Naples, the Ottoman Empire, the Papal States, Portugal, Russia, and Sweden. The French Republic, under the Directory, suffered from heavy levels of corruption and internal strife. The new republic also lacked funds, no longer enjoying the services of Lazare Carnot, the minister of war who had guided France to its victories during the early stages of the Revolution. Napoleon Bonaparte, commander of the Armée d'Italie in the latter stages of the First Coalition, had launched a campaign in Egypt, intending to disrupt the British control of India. Pressed from all sides, the Republic suffered a string of successive defeats against revitalised enemies, who were supported by Britain's financial help.
Sources: en.wikipedia.org
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.
The first four residues of Selank reproduce the tuftsin sequence Thr-Lys-Pro-Arg. A Pro-Gly-Pro extension at the C-terminus was added to slow enzymatic breakdown and extend residence time.
It holds marketing authorization in Russia, where nasal drop formulations are sold. No equivalent approval exists in the European Union, the United States, or most other countries.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.